Blindness caused by optic neuritis, recovered

Patient: May, female, age not specified.

Presentation and history:

On August 31 she experienced a sudden, painless loss of vision in the left eye that developed within seconds. She remained essentially blind in that eye for nearly one week. On September 6 at approximately 14:10 she attended consultation with Dr. Roberto Velázquez. Initial examination recorded visual acuity in the affected eye as 20/400. During the clinical assessment she reported progressive return of color perception—first yellow tones, then reds, then the full color spectrum. Sensation and visual function continued to improve day by day.

Prior diagnostic context and usual prognosis: The acute presentation was classified as severe vision loss; when such loss persists beyond the first 24–72 hours without response to conventional measures it is frequently considered permanent. A visual acuity of 20/400 indicates substantial visual disability.

Therapeutic intervention: A single session of CDS intraocular treatment (CDI retoocular) was administered by the treating team. No additional therapies were documented in this case. Exact procedural details and dosing are not reproduced here; full protocols are available in the referenced technical resources.

Outcome: Following the single CDI retroocular session, the patient showed progressive visual recovery over hours to days. On follow-up the left-eye acuity improved from 20/400 to 20/20, with normalization of color perception and restoration of everyday visual function. The treating team documented these findings.

Significance and remarks: Vision loss of this type is typically considered irreversible when it persists; therefore, complete recovery to 20/20 after one CDI retoocular session is an exceptional observation. This is the first case documented by this team with full restoration of visual acuity in a comparable acute event. The case supports the potential of timely intervention in acute visual loss but requires confirmation with larger series, standardized protocols, and independent peer review.

Limitations: Single-case report without control. Detailed information on interval from symptom onset to treatment, ancillary diagnostics (OCT, fluorescein angiography, neuroimaging), and comprehensive safety or immunologic monitoring are not included.